Quanome Technologies (QNME) investor relations material

Company overview and business model

• Focused on pharmaceutical distribution in China through Hupan Pharmaceutical, serving hospitals, distributors, and healthcare providers.

• Recently divested U.S. logistics operations to concentrate on pharmaceutical and quantum-enabled AI business lines.

• Exploring expansion into quantum-enabled artificial intelligence and post-quantum cryptography via Quantum Nexus Technologies Ltd.

• Operates as a Nevada holding company with subsidiaries in the PRC and Cayman Islands; all subsidiaries are wholly owned.

• Revenue is primarily derived from infusion products, specialty pharmaceuticals, and foods for special medical purposes.

Financial performance and metrics

• As of September 2, 2026, public float was approximately $23.85 million, with 34,427,559 shares held by non-affiliates.

• No dividends have been paid or declared; $12.7 million in funding provided to PRC subsidiaries to support operations.

• Market price of common stock has fluctuated between $0.2504 and $1.68 per share over the past year.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.

• Proceeds may be used to fund PRC subsidiaries, subject to regulatory approvals and restrictions.